Orexa Announces First Patient Dosed in Phase 2 Trial in Post-Operative Patients

Contributed by: PR Newswire

Tags

Orexa-Phase-2

More Like This

Orexo announces positive outcome from an in-vivo study of OX390

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

PR Newswire associated0

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Orexo to present clinical data for OX640 at the EAACI Congress

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

PR Newswire associated0

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

PR Newswire associated0

Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2